Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Lost in transition: A protocol for a retrospective, longitudinal cohort study for addressing challenges in opioid treatment for transition-age adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Background: In the United States, there has been a concerning rise in the prevalence of opioid use disorders (OUD) among transition-age (TA) adults, 18 to 25-years old, with a disproportionate impact on individuals and families covered by Medicaid. Of equal concern, the treatment system continues to underperform for many young people, emphasizing the need to address the treatment challenges faced by this vulnerable population at a pivotal juncture in their life course. Pharmacotherapy is the most effective treatment for OUD, yet notably, observational studies reveal gaps in the receipt of and retention in medications for opioid use disorder (MOUD), resulting in poor outcomes for many TA adults in treatment. Few current studies on OUD treatment quality explicitly consider the influence of individual, organizational, and contextual factors, especially for young people whose social roles and institutional ties remain in flux.
      Methods: We introduce a retrospective, longitudinal cohort design to study treatment quality practices and outcomes among approximately 65,000 TA adults entering treatment for OUD between 2012 and 2025 in New York. We propose to combine data from multiple sources, including Medicaid claims and encounter data and a state registry of substance use disorder (SUD) treatment episodes, to examine three aspects of OUD treatment quality: 1) MOUD use, including MOUD option (e.g., buprenorphine, methadone, or extended-release [XR] naltrexone); 2) adherence to pharmacotherapy and retention in treatment; and 3) adverse events (e.g., overdoses). Using rigorous analytical methods, we will provide insights into how variation in treatment practices and outcomes are structured more broadly by multilevel processes related to communities, treatment programs, and characteristics of the patient, as well as their complex interplay.
      Discussion: Our findings will inform clinical decision making by patients and providers as well as public health responses to the rising number of young adults seeking treatment for OUD amidst the opioid and polysubstance overdose crisis in the U.S.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Aleksanyan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Addiction. 2003 May;98(5):673-84. (PMID: 12751985)
      Milbank Q. 2016 Jun;94(2):237-41. (PMID: 27265554)
      Am J Psychiatry. 2020 Feb 1;177(2):117-124. (PMID: 31786933)
      Addiction. 2016 Aug;111(8):1406-15. (PMID: 26918564)
      Drug Alcohol Depend. 2012 Jun 1;123(1-3):72-8. (PMID: 22093488)
      J Addict Med. 2014 May-Jun;8(3):176-82. (PMID: 24695018)
      JAMA. 1988 Sep 23-30;260(12):1743-8. (PMID: 3045356)
      J Environ Public Health. 2011;2011:948789. (PMID: 21776440)
      Am Psychol. 2000 May;55(5):469-80. (PMID: 10842426)
      Biometrics. 2000 Dec;56(4):1016-22. (PMID: 11129456)
      Drug Alcohol Depend. 2021 May 1;222:108666. (PMID: 33766440)
      Psychiatr Serv. 2011 Nov;62(11):1273-81. (PMID: 22211205)
      Inquiry. 1988 Spring;25(1):173-92. (PMID: 2966122)
      PLoS Med. 2019 Nov 26;16(11):e1002969. (PMID: 31770387)
      J Subst Abuse Treat. 2021 Jul;126:108329. (PMID: 34116820)
      Eval Health Prof. 2014 Jun;37(2):147-55. (PMID: 24492245)
      Drug Alcohol Depend. 2018 Oct 1;191:145-151. (PMID: 30107320)
      N Engl J Med. 2016 Dec 22;375(25):2413-2415. (PMID: 27959718)
      J Subst Abuse Treat. 2013 May-Jun;44(5):473-80. (PMID: 23217610)
      MMWR Morb Mortal Wkly Rep. 2015 Jul 10;64(26):719-25. (PMID: 26158353)
      J Behav Health Serv Res. 2020 Oct;47(4):464-475. (PMID: 32350800)
      Drug Alcohol Depend. 2020 Aug 1;213:108087. (PMID: 32492601)
      J Addict Dis. 2016;35(1):22-35. (PMID: 26467975)
      Clin Psychol Rev. 2013 Dec;33(8):1010-24. (PMID: 24029221)
      Subst Abuse Treat Prev Policy. 2020 Jun 18;15(1):42. (PMID: 32552836)
      Subst Abuse Treat Prev Policy. 2019 Jun 25;14(1):28. (PMID: 31238952)
      Epidemiol Rev. 2020 Jan 31;42(1):41-56. (PMID: 32239206)
      Pediatrics. 2016 Sep;138(3):. (PMID: 27550978)
      J Subst Abuse Treat. 2015 Oct;57:75-80. (PMID: 25997674)
      Health Aff (Millwood). 2020 May;39(5):747-755. (PMID: 32364847)
      J Adolesc Health. 2020 Dec;67(6):735-736. (PMID: 33220792)
      Am J Drug Alcohol Abuse. 2019;45(1):1-10. (PMID: 30675818)
      Addiction. 2021 Mar;116(3):548-557. (PMID: 32621368)
      Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209. (PMID: 19588333)
      Pediatrics. 2021 Jan;147(Suppl 2):S215-S219. (PMID: 33386324)
      Pediatrics. 2021 Jan;147(Suppl 2):S195-S203. (PMID: 33386322)
      Dev Cogn Neurosci. 2016 Feb;17:103-17. (PMID: 26774291)
      Drug Alcohol Depend. 2020 Aug 1;213:108130. (PMID: 32593972)
      J Subst Abuse Treat. 2015 Mar;50:50-8. (PMID: 25456091)
      Drug Alcohol Depend. 2014 Oct 1;143:181-8. (PMID: 25150401)
      J Subst Abuse Treat. 2003 Oct;25(3):125-34. (PMID: 14670518)
      Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89. (PMID: 25747921)
      Subst Abus. 2019;40(4):453-458. (PMID: 31361592)
      Qual Health Res. 2017 Sep;27(11):1614-1627. (PMID: 27920355)
      JAMA Pediatr. 2017 Aug 1;171(8):747-755. (PMID: 28628701)
      Psychol Addict Behav. 2017 May;31(3):242-254. (PMID: 28318279)
      Pediatrics. 2021 Jan;147(Suppl 2):S249-S258. (PMID: 33386327)
      Subst Abuse Treat Prev Policy. 2020 Aug 14;15(1):58. (PMID: 32795372)
      Am J Psychiatry. 2003 Jun;160(6):1041-52. (PMID: 12777258)
      Eval Program Plann. 2011 Nov;34(4):375-81. (PMID: 21371752)
      JAMA Pediatr. 2018 Nov 1;172(11):1029-1037. (PMID: 30208470)
      Behav Med. 2000 Fall;26(3):129-38. (PMID: 11209593)
      Lancet. 2016 Sep 24;388(10051):1260-1. (PMID: 27673455)
      Science. 2018 Sep 21;361(6408):. (PMID: 30237320)
      Addiction. 2003 Mar;98(3):325-37. (PMID: 12603232)
      Drug Alcohol Depend. 2008 Apr 1;94(1-3):199-206. (PMID: 18243585)
      JAMA. 2000 Mar 8;283(10):1303-10. (PMID: 10714729)
      J Subst Abuse Treat. 2006 Oct;31(3):221-33. (PMID: 16996385)
      J Addict Med. 2018 May/Jun;12(3):170-183. (PMID: 29432333)
      J Health Soc Behav. 1995;Spec No:80-94. (PMID: 7560851)
      Am J Epidemiol. 2013 Apr 1;177(7):675-82. (PMID: 23445901)
      Subst Abus. 2012;33(1):9-18. (PMID: 22263709)
      J Addict Med. 2015 Sep-Oct;9(5):358-67. (PMID: 26406300)
      Addict Behav. 2011 Jun;36(6):584-589. (PMID: 21377275)
      J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):22-31. (PMID: 21156267)
      J Subst Abuse Treat. 2014 Sep;47(3):202-12. (PMID: 24953168)
      J Child Psychol Psychiatry. 2021 Apr;62(4):437-440. (PMID: 32803755)
      Clin Ther. 2019 Sep;41(9):1669-1680. (PMID: 31462387)
      BMC Pediatr. 2018 May 4;18(1):151. (PMID: 29728088)
      JAMA. 2008 Nov 5;300(17):2003-11. (PMID: 18984887)
      Int J Ment Health Addict. 2013 Feb 1;11(1):110-122. (PMID: 23956702)
      Am Psychol. 1992 Jan;47(1):6-22. (PMID: 1539925)
      J Addict Med. 2015 Nov-Dec;9(6):470-7. (PMID: 26517324)
      J Adolesc Health. 2020 Dec;67(6):778-785. (PMID: 32873500)
      J Adolesc Health. 2020 Oct;67(4):542-549. (PMID: 32336560)
      J Behav Health Serv Res. 2013 Jul;40(3):367-77. (PMID: 23702611)
      Pediatrics. 2021 Jan;147(Suppl 2):S268-S270. (PMID: 33386331)
      Drug Alcohol Depend. 2018 Sep 1;190:170-178. (PMID: 30041092)
      J Subst Abuse Treat. 2020 Jul;114:108028. (PMID: 32527510)
      J Adolesc Health. 2023 Jan;72(1):105-110. (PMID: 36216678)
      Eval Rev. 2007 Dec;31(6):548-63. (PMID: 17986707)
      Pediatrics. 2021 Jan;147(Suppl 2):S204-S214. (PMID: 33386323)
      JAMA. 2000 Oct 4;284(13):1689-95. (PMID: 11015800)
      J Adolesc Health. 2017 Jun;60(6):747-750. (PMID: 28258807)
      Arch Gen Psychiatry. 2011 Dec;68(12):1238-46. (PMID: 22065255)
      Addiction. 2004 Oct;99(10):1286-97. (PMID: 15369567)
      Drug Alcohol Depend. 1999 Dec 1;57(2):151-66. (PMID: 10617099)
      J Subst Abuse Treat. 2021 Jan;120:108159. (PMID: 33298299)
    • Grant Information:
      R01 DA057267 United States DA NIDA NIH HHS
    • الرقم المعرف:
      0 (Analgesics, Opioid)
      40D3SCR4GZ (Buprenorphine)
      UC6VBE7V1Z (Methadone)
    • الموضوع:
      Date Created: 20240814 Date Completed: 20240814 Latest Revision: 20240923
    • الموضوع:
      20240923
    • الرقم المعرف:
      PMC11324150
    • الرقم المعرف:
      10.1371/journal.pone.0297567
    • الرقم المعرف:
      39141672